Factor Model (net +1.3)
Factor Model
net +1.3 3.0 / 10Redmile Doubles Down on Clinical Biotech Upswing
Watch: The path to varegacestat approval — Immunome will need to file and navigate FDA review, likely 12-18 months out. Watch also for any Phase 3 data readouts from the rest of the pipeline and whether the $400 million burn rate sustains clinical progress without another dilutive raise.
Redmile Group added $12.2 million to its IMNM stake in Q4 2025, raising it to 9.05% of assets under management and signaling institutional confidence in the clinical-stage immunotherapy player. The bet comes after Immunome stock surged 120% over the past year versus the S&P 500's 13% gain. The catalyst: December Phase 3 RINGSIDE results showing varegacestat cut progression or death risk by 84% in desmoid tumors with a 56% response rate, validating the core franchise. Immunome banked $400 million gross from a capital raise at $21.50 per share to fuel its oncology pipeline.
Redmile's concentrated bet — now its 9th largest position — suggests the fund believes Immunome's Phase 3 data is durable enough to justify a 9% weighting in a diversified biotech portfolio. The positioning matters: an 18-month rally followed by institutional capital backing doesn't guarantee approval (regulatory risk remains), but it signals the market is pricing a meaningful probability of success.
Evidence
7 older signals
Fundamentals & Data ▾
Recent transactions
Get alerted when IMNM changes direction
We'll email you when our AI detects a shift — reversals, insider clusters, filing red flags.